Tag:
Elan
Latest Headlines
Latest Headlines
UPDATED: Elan chases a holy grail of Alzheimer's treatment: Prevention
Elan's support of research at Cambridge University could unlock targets for a drug that offers a preventive treatment for the memory-stealing disease and other illnesses involving misfolding proteins in the brain.
Elan chief to stick around until Alzheimer's data breaks
Kelly Martin is hanging on to his executive suite at Elan ( $ELN ) for a few more months. Instead of bowing out May 1 under a longstanding exit plan, Martin has agreed to keep the title and the...
Elan CEO puts retirement party on hold as Alzheimer's PhIII looms
Kelly Martin is hanging on to his executive suite at Elan ( $ELN ) for a few more months. Instead of bowing out May 1 under a longstanding exit plan, Martin has agreed to keep the title and the...
J&J backs potential pain drugs derived from spider venom
One industry watcher called it "SpideRx." Johnson & Johnson ( $JNJ ) has struck a deal with Australia's Queensland University to research spider venom peptides as remedies for chronic pain--a
Quest's companion diagnostic confronts Tysabri brain infection risk
It's a vexing problem that certain drugs with enormous benefit can also carry significant health risk. Case in point: Some patients who take the multiple sclerosis drug Tysabri experience improved
Strong sales from Bayer pharma, Allergan's Botox, Novo's Victoza
No fewer than 10 drug companies reported new numbers over the last 24 hours. Bayer's pharma sales are up. Allergan's Botox drug is still defying the economic crisis. Elan saw an earnings hike on the
After restructuring, Elan focuses on its R&D priorities
For years Elan has struggled to deliver for its investors--with little success. It spent quite some time talking about restructuring without actually accomplishing much. It had to deal with a severe
Flying high on Elan deal, Alkermes gets to work on Big Pharma project
Alkermes ( $ALKS ) is taking immediate occupancy of an Elan Drug Technologies' Athalone, Ireland, facility following its $1 billion acquisition of the latter's drug technology business. Alkermes
Analysis: Alkermes aims at 'Big Biotech' status with EDT buyout
Xconomy examines Alkermes' ( $ALKS ) new company strategy in the wake of its acquisition of Elan Drug Technologies. The EDT buyout, explains Luke Timmerman, gives the biotech a steady revenue flow to
Proteostasis lands $50M neurodegenerative disease pact with Elan
Intrigued by the broad potential of Proteostasis Therapeutics' development platform to create new drugs to treat a broad range of neurodegenerative disorders, Ireland's Elan has stepped up with a $50
